I rarely respond to posters like you who have said they have had no position despite posting endlessly 24/7 for year in this board, but I am sometimes no so strictly disciplined.
Linda Liau said in essence regarding those 100 patients who have lived over three years that "the majority of them not only live long term but also live progression free." [these are unprecedented, never seen in other trials!]
Based on the blinded data and subsequent update, it indicates it is highly likely that about 20% of all the patient population in the trial have lived and will live over 5 years.
Patients experience flu like symptom after injection of DCVax-L or placebo. Investigators will be quite sure how things are going from MRIs, blood analyses regarding possible immunogenicity activities of patients due to, oh, not placebo plus stand of care, but DCVax-L.
Adequately more data and evidence strongly indicate DCVax-L is safe and efficacious.
So chew the information, slowly and conscientiously, for I don't want your reply.
And please come to this board and let me know what's the result of your chewing after topline data is released, which I believe may come in August the earliest, and Nov the latest.
Market Data 
Markets 
AI
